[Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation]

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Understanding the molecular mechanisms driving MM progression is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the expression of cell division cycle protein 37 (Cdc37) in multiple myeloma (MM).
• To determine the effect of Cdc37 on MM cell proliferation and cell cycle regulation.
• To elucidate the potential role of the NF-κB signaling pathway in Cdc37-mediated effects on MM.

Main Methods:

• Real-time quantitative PCR (RT-qPCR) to measure Cdc37 mRNA expression in patient samples.
• Lentivirus-mediated shRNA to down-regulate Cdc37 in the NCI-H929 MM cell line.
• In vitro proliferation assays (CCK-8, soft agar) and in vivo tumorigenesis models in mice.
• Flow cytometry for cell cycle analysis and Western blot for cell cycle-associated proteins and NF-κB pathway components.

Main Results:

• Cdc37 mRNA expression was significantly higher in CD138+ cells from newly diagnosed MM patients compared to healthy individuals.
• Down-regulation of Cdc37 in NCI-H929 cells led to decreased proliferation both in vitro and in vivo.
• Cdc37 inhibition resulted in G0/G1 phase arrest, decreased cyclin D1, and increased p21 and p53 expression.
• Activation of the NF-κB signaling pathway was suppressed following Cdc37 down-regulation.

Conclusions:

• Cdc37 is overexpressed in newly diagnosed multiple myeloma patients.
• Inhibition of Cdc37 significantly reduces MM cell proliferation and induces G0/G1 cell cycle arrest.
• The observed effects of Cdc37 inhibition may be mediated through the suppression of NF-κB signaling pathway activation.